For the quarter ending 2025-09-30, BMRN had $36,292K increase in cash & cash equivalents over the period. $340,238K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 776,133 | - | - | - |
| Cost of sales | 140,085 | - | - | - |
| R&d expenses-Research And Early Pipeline | 93,720 | - | - | - |
| R&d expenses-Later Stage Clinical Programs | 251,650 | - | - | - |
| R&d expenses-Marketed Products | 64,108 | - | - | - |
| S&m expenses | 131,327 | - | - | - |
| G&a expenses | 137,088 | - | - | - |
| Other segment expense (income), net | -11,101 | - | - | - |
| Net income | -30,744 | 240,532 | 185,686 | 124,943 |
| Non-cash changes in the fair value of contingent consideration | - | - | - | 0 |
| Depreciation and amortization | 18,487 | 18,563 | 22,069 | 23,607 |
| Non-cash interest expense | 649 | 660 | 660 | 660 |
| Accretion of discount on investments | 978 | 1,355 | 1,362 | 1,726 |
| Stock-based compensation | 49,265 | 47,531 | 37,700 | 51,919 |
| Gain on sale of nonfinancial assets | 0 | 0 | 0 | 0 |
| Impairment of assets and other noncash adjustments | 0 | 0 | 2,967 | - |
| Acquired in-process research & development expense | 220,963 | - | - | - |
| Deferred income taxes | -13,646 | 33,342 | 28,429 | 42,387 |
| Unrealized foreign exchange gain | -5,550 | -4,720 | 10,026 | -5,599 |
| Other | -212 | 649 | 1,267 | -21,389 |
| Accounts receivable, net | -48,746 | 98,534 | 57,590 | -72,547 |
| Inventory | 26,334 | 48,127 | 24,335 | 34,271 |
| Other current assets | 17,033 | 8,765 | 6,327 | -16,161 |
| Other assets | 19,174 | 11,881 | 1,624 | 41,861 |
| Accounts payable and accrued liabilities | 116,367 | 5,766 | -2,655 | -100,259 |
| Impairment of assets and other non-cash adjustments | - | - | - | 0 |
| Other long-term liabilities | 16,355 | 3,468 | 2,069 | 4,532 |
| Net cash provided by operating activities | 368,685 | 185,271 | 174,394 | 185,627 |
| Purchases of property, plant and equipment | 28,447 | 17,101 | 16,768 | 19,530 |
| Maturities and sales of investments | 98,809 | 117,934 | 77,804 | 154,582 |
| Purchases of investments | 110,829 | 113,159 | 89,274 | 57,879 |
| Proceeds from sale of nonfinancial assets | 0 | 0 | 0 | 0 |
| Purchase of intangible assets | 5,303 | 266 | 0 | 769 |
| Acquisition, net of cash acquired | 285,193 | - | - | - |
| Other | 0 | - | - | 0 |
| Net cash provided by (used in) investing activities | -330,963 | -12,592 | -28,238 | 76,404 |
| Proceeds from exercises of awards under equity incentive plans | 7 | 7,707 | 0 | 7,862 |
| Taxes paid related to net share settlement of equity awards | 2,176 | 12,310 | 38,779 | 4,909 |
| Repayments of convertible debt | 0 | - | - | 0 |
| Payments of contingent consideration | - | - | - | 0 |
| Other | 0 | 0 | 0 | -94 |
| Net cash used in financing activities | -2,169 | -4,603 | -38,779 | 2,859 |
| Effect of exchange rate changes on cash | 739 | -3,063 | -1,416 | 2,504 |
| Net increase (decrease) in cash and cash equivalents | 36,292 | 165,013 | 105,961 | 267,394 |
| Cash and cash equivalents at beginning of period | 942,842 | - | - | - |
| Cash and cash equivalents at end of period | 1,250,108 | - | - | - |
BIOMARIN PHARMACEUTICAL INC (BMRN)
BIOMARIN PHARMACEUTICAL INC (BMRN)